0T20 Stock Chart & Stats
€6.60
€0.00(0.00%)
At close: 4:00 PM EDT
€6.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.40 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.13M
Enterprise Value€8.37M
Total Cash (Recent Filing)€3.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 12, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding15,368,277
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.89Price Target Upside-86.47% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetNo reported debt reduces refinancing and solvency pressure, giving the company greater flexibility while it advances research programs. This limits fixed financial obligations and preserves more capacity to direct available resources toward development and other corporate needs.
Flexible Capital AccessThe equity facility creates a potentially meaningful, controlled source of financing for product development and general operations over up to 36 months. Although issuance can dilute ownership, access to capital may extend execution capacity for the pipeline beyond current resources.
Lead Program AdvancementProgress toward a Phase 2a human influenza challenge study represents a concrete development milestone for the lead candidate. Advancing into clinical testing could generate important program evidence and improve the company’s ability to validate its antiviral pipeline.
Bears Say
Persistent Cash BurnConsistently negative operating and free cash flow shows that the business is not currently self-funding its activities. The sharp 2025 deterioration increases dependence on external financing and can constrain how long the company sustains research without additional capital.
Negative EquityNegative equity indicates accumulated losses or write-downs have overwhelmed the company’s capital base. This weakens financial resilience, limits flexibility during development setbacks, and may make future financing more important as Traws continues operating without commercial revenue.
Clinical And Regulatory Execution RiskThe FDA clinical hold and required MHRA toxicology resubmission create material uncertainty around the timing of human testing for the lead program. Delays in resolving these issues could postpone clinical milestones and extend the period before the pipeline can demonstrate value.
Traws Pharma News
0T20 FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was €6.40 and its highest was €6.60 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is €4.13M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 12 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Aug 14, 2026. The company reported -€0.143 earnings per share for the quarter, beating the consensus estimate of -€0.299 by €0.156.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Overvalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.18.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,368,277 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -€0.143 in its last earnings report, beating expectations of -€0.299. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in DE:0T20
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
0T20 Stock 12 Month Forecast
Average Price Target
€0.89
▼(-86.47% Downside)